US2014039019A1PendingUtilityA1

Methods of Using Ryanodine Antagonists in Treating Neural Injury

43
Assignee: ALLERGAN INCPriority: Jul 3, 2002Filed: Oct 7, 2013Published: Feb 6, 2014
Est. expiryJul 3, 2022(expired)· nominal 20-yr term from priority
Inventors:Cun-Jian DongWilliam Hare
A61P 25/16A61K 31/4178A61P 27/06A61P 25/00A61P 25/28A61P 27/02A61K 31/4166
43
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides a method of providing neuroprotection to a mammal comprising administering to said mammal suffering from or at risk of suffering a noxious action on its nerve cells an effective amount of a ryanodine antagonist, e.g. dantrolene, to inhibit or prevent nerve cell injury or death.

Claims

exact text as granted — not AI-modified
1 - 16 . (canceled) 
     
     
         17 . A method for treating retinal ganglion cell loss in a patient comprising administering dantrolene to said patient. 
     
     
         18 . The method according to  claim 17 , wherein said administering comprises oral administration. 
     
     
         19 . The method according to  claim 17  wherein said administering comprises intravitreal injection. 
     
     
         20 . The method according to  claim 17  wherein said administering comprises topical administration of an ophthalmic solution of the dantrolene to the eye. 
     
     
         21 . The method according to  claim 17 , wherein the dantrolene is in the form of an aqueous solution, a suspension, a gel, or a jelly.

Join the waitlist — get patent alerts

Track US2014039019A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.